Novel Personalized AMD and Diabetic Retinopathy Treatment

Willner Itamar, HUJI, Faculty of Science, The Institute of Chemistry


Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) are leading causes of blindness in the Western world. Both are characterized by pathological angiogenesis in the various eye structures.

With high prevalence  in  diabetes population, the burden in form of direct and indirect management cost of diabetic retinopathy is a significant challenge.

Current treatment for AMD and DR includes monthly intraocular injection of various anti-VEGF agents. Over the past few years, a novel biological drug family based on nucleic acid-based ligands, Aptamers, is proven for use in ophthalmology.

Although these new treatments are promising, they have severe limitations: not only they involved complicated surgical procedure, but  they are also performed without direct measurement of disease biomarkers in different patients. Therefore, there is still a high demand for more personalized and safer approach to improve efficiency and compliancy.

Our Innovation

Non-invasive method of personalized diagnosis and treatment of ocular disease, Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) using novel nanoparticle-mediated delivery of Aptamers

Nanoparticles mediated penetration functioning on the same scale as ocular transport molecular processes holds promise of topical noninvasive patient compliant next generation of VEGF Aptamer to fight AMD-induced blindness risks. 


  • Topical delivery.
  • Personalized angiogenesis-regulated delivery to revolutionize Aptamers drugs field.

Patent Status

Published US-2020/0000934-A1

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
Contact ME: